FutureChem Obtains Patent Rights for Prostate Cancer Diagnostic New Drug in 32 European Countries

[Asia Economy Reporter Lee Gwan-joo] FutureChem, a specialist company in radiopharmaceuticals, announced on the 17th that it has obtained patent rights for ‘18F-Labeled Compounds for Diagnosis of Prostate Cancer and Use Thereof’ in 32 European countries.

FutureChem has succeeded in registering the sixth overseas patent, including domestic patents for the prostate cancer diagnostic drug 'FC303' as well as patents in Australia and the United States. The patent has been filed in major countries worldwide and is currently under examination.

Prostate cancer is one of the most common cancers among men, ranking first in incidence in the United States, fifth in South Korea, and second worldwide among male cancers. FC303 uses a radioactive isotope with a short half-life and selectively accumulates only in prostate cancer, making it advantageous not only for early diagnosis and treatment evaluation of prostate cancer but also for detecting metastasis and recurrence, according to the company.

FC303 completed its Phase 1 clinical trial in the United States last month and is currently undergoing Phase 3 clinical trials in South Korea. FutureChem has applied to the Ministry of Food and Drug Safety for an additional Phase 3 clinical trial to expand the indication to Biochemically Recurrent Prostate Cancer (BRPC) in high-risk prostate cancer patients.

A FutureChem official stated, "Overseas technology licensing agreements are continuously being made, and through the registration of overseas patents accordingly, we are steadily establishing a foundation for entry into the global market."

This content was produced with the assistance of AI translation services.